Novo Nordisk Q2 2024 GAAP EPS DKK 4.49 Misses DKK 5.05 Estimate, Sales DKK 68.060B Miss DKK 68.654B Estimate
Portfolio Pulse from Benzinga Newsdesk
Novo Nordisk (NYSE:NVO) reported Q2 2024 earnings per share (EPS) of DKK 4.49, missing the analyst estimate of DKK 5.05 by 11.09%. Sales were DKK 68.060 billion, also missing the estimate of DKK 68.654 billion by 0.87%. Despite the misses, EPS increased by 3.94% and sales by 25.34% year-over-year.
August 07, 2024 | 6:45 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novo Nordisk's Q2 2024 earnings and sales both missed analyst estimates, with EPS missing by 11.09% and sales by 0.87%. Despite these misses, the company showed year-over-year growth in both EPS and sales.
The misses on both EPS and sales estimates are likely to put short-term pressure on Novo Nordisk's stock price. However, the year-over-year growth in both metrics may mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100